These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

567 related items for PubMed ID: 17065670

  • 1. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
    Triplitt C, Glass L, Miyazaki Y, Wajcberg E, Gastaldelli A, De Filippis E, Cersosimo E, DeFronzo RA.
    Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
    [Abstract] [Full Text] [Related]

  • 2. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes.
    Vinik AI, Zhang Q.
    Diabetes Care; 2007 Apr; 30(4):795-800. PubMed ID: 17259481
    [Abstract] [Full Text] [Related]

  • 3. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [Abstract] [Full Text] [Related]

  • 4. Efffect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycemic control in type 2 diabetic patients.
    Yang J, Di F, He R, Zhu X, Wang D, Yang M, Wang Y, Yuan S, Chen J.
    Chin Med J (Engl); 2003 May; 116(5):785-7. PubMed ID: 12875702
    [Abstract] [Full Text] [Related]

  • 5. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y, DeFronzo RA.
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [Abstract] [Full Text] [Related]

  • 6. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
    Dashora UK, Sibal L, Ashwell SG, Home PD.
    Diabet Med; 2007 Apr; 24(4):344-9. PubMed ID: 17298589
    [Abstract] [Full Text] [Related]

  • 7. The effect of pioglitazone on the liver: role of adiponectin.
    Gastaldelli A, Miyazaki Y, Mahankali A, Berria R, Pettiti M, Buzzigoli E, Ferrannini E, DeFronzo RA.
    Diabetes Care; 2006 Oct; 29(10):2275-81. PubMed ID: 17003306
    [Abstract] [Full Text] [Related]

  • 8. 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes.
    Vehkavaara S, Yki-Järvinen H.
    Arterioscler Thromb Vasc Biol; 2004 Feb; 24(2):325-30. PubMed ID: 14684428
    [Abstract] [Full Text] [Related]

  • 9. Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes.
    Peters Harmel AL, Kendall DM, Buse JB, Boyle PJ, Marchetti A, Lau H.
    Curr Med Res Opin; 2004 Feb; 20(2):215-23. PubMed ID: 15006017
    [Abstract] [Full Text] [Related]

  • 10. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G, Issa M, Vlajnic A.
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [Abstract] [Full Text] [Related]

  • 11. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.
    McCluskey D, Touger MS, Melis R, Schleusener DS, McCluskey D.
    Clin Ther; 2004 Nov; 26(11):1783-90. PubMed ID: 15639690
    [Abstract] [Full Text] [Related]

  • 12. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.
    Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Piccinni MN, Fogari E, Salvadeo S, Ciccarelli L, Fogari R.
    Diabetes Res Clin Pract; 2005 Jul; 69(1):5-13. PubMed ID: 15955382
    [Abstract] [Full Text] [Related]

  • 13. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
    Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA.
    Diabetologia; 2001 Dec; 44(12):2210-9. PubMed ID: 11793023
    [Abstract] [Full Text] [Related]

  • 14. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
    Kadoglou NP, Kapelouzou A, Tsanikidis H, Vitta I, Liapis CD, Sailer N.
    Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
    [Abstract] [Full Text] [Related]

  • 15. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
    Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H.
    Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
    Basu R, Shah P, Basu A, Norby B, Dicke B, Chandramouli V, Cohen O, Landau BR, Rizza RA.
    Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
    [Abstract] [Full Text] [Related]

  • 17. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [Abstract] [Full Text] [Related]

  • 18. Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study.
    Hausmann M, Dellweg S, Osborn C, Heinemann L, Buchwald A, Rosskamp R, Genova P, Heise T.
    Diabetes Obes Metab; 2006 Sep; 8(5):574-80. PubMed ID: 16918593
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy.
    Yokoyama H, Tada J, Kamikawa F, Kanno S, Yokota Y, Kuramitsu M.
    Diabetes Res Clin Pract; 2006 Jul; 73(1):35-40. PubMed ID: 16513202
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.
    González-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R, Wacher-Rodarte N, Martínez-Abundis E, Aguilar-Salinas C, Islas-Andrade S, Arechavaleta-Granell R, González-Canudas J, Rodríguez-Morán M, Zavala-Suárez E, Ramos-Zavala MG, Metha R, Revilla-Monsalve C, Beltrán-Jaramillo TJ.
    J Diabetes Complications; 2009 Jul; 23(6):376-9. PubMed ID: 18849173
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.